-
Ebb & Flow More details, please Investors were underwhelmed last week after Actelion Ltd. (SIX:ATLN) outlined plans to return to earnings growth. Actelion fell CHF0.80 to CHF39.10, after gaining 14% the prior week …
Published on 5/14/2012
-
Ebb & Flow Royalties don't dilute Swiss biotech investor BB Biotech AG (SIX:BION; Xetra:BBZA) expects Intercell AG (VSE:ICLL; OTCQX:INRLY) to reach profitability with last week's infusion of €25 million ($32.5 …
Published on 5/14/2012
-
Vertex the odds-on favorite Money Raised in 2012 Last week, the biotech industry raised $310 million, bringing to $11.6 billion the total raised year-to-date. In 2011, a total of $49.5 billion was raised, including…
Published on 5/14/2012
-
Vertex the odds-on favorite Earnings on deck At least three biotechs and pharmas are slated to report earnings this week. Chinese biosimilars play 3SBio Inc. (NASDAQ:SSRX) is expected to report a 33% jump in …
Published on 5/14/2012
-
Vertex the odds-on favorite EPS watch At least 13 biotechs and pharmas reported earnings last week. While not yet profitable, Dendreon Corp. (NASDAQ:DNDN) lost a fifth of its valuation, or $335 million, after it did…
Published on 5/14/2012
-
Vertex the odds-on favorite Thinning the pipeline Actelion Ltd. (SIX:ATLN) last week said it plans to focus R&D on specialty products, including Orphan diseases, immunomodulators and antibiotics, and out-license …
Published on 5/14/2012
-
Ebb & Flow Life sciences leverage Oxford Finance LLC has leveraged a deep-pocketed parent company and consistent returns from issuing debt to development-stage life sciences companies to amass $530 million in new …
Published on 5/14/2012
-
Ebb & Flow Regulatory milestones Arena Pharmaceuticals Inc. (NASDAQ:ARNA) was up $3.77 (146%) to $6.36 last week, including a $2.70 (74%) jump on Friday after an FDA panel voted 18-4, with one abstention, that the …
Published on 5/14/2012
-
Ebb & Flow The lure of research The Tel Aviv Stock Exchange is planning to provide analyst research reports for its listed life sciences companies as part of an effort to attract dual-listings for U.S. companies on …
Published on 5/14/2012
-
Table: Thinning the pipeline Table: Earnings on deck Figure: Money Raised in 2012 Table: EPS watch Investors think there's still room to …
Published on 5/14/2012
-
Ebb & Flow Back together again Dutch bank ABN AMRO Bank N.V. has reacquired the M&A, advisory, equity brokerage and capital structuring capabilities in the Netherlands that it sold in 2007 to a consortium led by the…
Published on 5/7/2012
-
Ebb & Flow Earnings on deck At least 10 biotechs and pharmas are slated to report earnings this week. Salix Pharmaceuticals Ltd. (NASDAQ:SLXP), Simcere Pharmaceutical Group (NYSE:SCR) and Teva Pharmaceutical …
Published on 5/7/2012
-
Ebb & Flow Venture tracks Scott Morenstein was promoted to managing director at Valence Life Sciences. He was principal at Caxton Advantage Venture Partners. Valence was formed in February by the founders of Caxton.…
Published on 5/7/2012
-
Table: Earnings on deck Figure: Money raised in 2012 Table: EPS Watch The former shareholders of Fumapharm AG could be looking forward to …
Published on 5/7/2012
-
Liquidnet, a dark pool trading platform, is targeting small cap healthcare companies with its data on demand for shares and ability to place large blocks with long-only institutional funds.
Published on 5/7/2012
-
Ebb & Flow Money Raised in 2012 Last week, the biotech industry raised $200 million, bringing to $11.4 billion the total raised year-to-date. In 2011, a total of $49.5 billion was raised, including $37.2 billion in …
Published on 5/7/2012
-
Ebb & Flow EPS watch At least 22 biotechs and pharmas reported earnings last week, with 16 losing more than $9.3 billion in aggregate market value. Twelve of the 16 companies reported EPS and/or revenues that missed…
Published on 5/7/2012
-
Ebb & Flow Trusting in M&A International Biotechnology Trust plc (LSE:IBT) has been particularly successful riding the recent wave of biotech M&A. Last month's proposed deals for specialty pharma EUSA Pharma Inc. …
Published on 5/7/2012
-
Ebb & Flow Regulatory milestones Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) gained $1.33 (11%) to $13.77 last week after FDA accepted for review an NDA for lomitapide to treat homozygous familial …
Published on 5/7/2012
-
Ebb & Flow Analyst tracks Joshua Schimmer departed Leerink Swann, where he was a managing director and biotechnology research analyst. Banker tracks Michael Manocchio was promoted to VP from associate at Morgan …
Published on 4/30/2012
-
Ebb & Flow Convergence Amgen Inc. (NASDAQ:AMGN) and new partner AstraZeneca plc (LSE:AZN; NYSE:AZN) are crossing paths in more ways than one.The biotech gained $2.5 billion in market cap to $56.7 billion last week, …
Published on 4/30/2012
-
Ebb & Flow Money Raised in 2012 Last week, the biotech industry raised $175 million, bringing to $11.1 billion the total raised year-to-date. In 2011, a total of $49.5 billion was raised, including $37.2 billion in …
Published on 4/30/2012
-
Ebb & Flow Earnings on deck At least 18 profitable biotechs and pharmas are slated to report earnings this week. The Street is projecting double-digit EPS growth for specialty pharmas Allergan Inc. (NYSE:AGN) and …
Published on 4/30/2012
-
Ebb & Flow EPS watch At least 27 biotechs and pharmas reported earnings last week. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), both with newly launched drugs, tacked …
Published on 4/30/2012
-
Ebb & Flow Long view on China Fidelity Growth Partners Asia thinks longer can be better in Chinese investments, and expects a single LP, global reach and an established presence will allow it to take an extended …
Published on 4/30/2012